Biogen Idec Plans Multiple Sclerosis Portfolio Expansion
Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.
Aside from the marketed Avonex and Tysabri, Biogen is pursuing three other treatments through partnerships and acquisitions.